|Videos|December 25, 2019
HER2+ mBC: DESTINY-Breast04 Trial
Author(s)Sponsored Content
The comparison of trastuzumab deruxtecan (DS-8201a) with standard chemotherapy is examined for patients with low levels of HER2 metastatic breast cancer and final thoughts on the future treatment landscape of HER2+ breast cancer.
Advertisement
The comparison of trastuzumab deruxtecan (DS-8201a) with standard chemotherapy is examined for patients with low levels of HER2 metastatic breast cancer and final thoughts on the future treatment landscape of HER2+ breast cancer.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on CURE
1
Most Patients With HER2+ Breast Cancer Miss Standard Treatment, Study Shows
2
Expert insights into Biomarker-Driven Care and Emerging Targets in GI Cancer
3
FDA Fast Tracks LBL-034 in Relapsed or Refractory Multiple Myeloma
4
Study Identifies Why Some Breast Cancers Resist Enhertu Treatment
5